Competition getting stiff for DPP-4 inhibitors

Following Bristol-Myers Squibb’s Onglyza (saxagliptin), Boehringer Ingelheim finally won the approval of the Korea Food and Drug Administration for their diabetes drug Trajenta (linagliptin), a dipeptidyl peptidase 4 (DPP-4) inhibitor that will directly compete with Merck's fast-growing treatment, Januvia.

And there's no doubt that the drug makers aim for Onglyza and Trajenta to steal Januvi...